Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers

@article{Embil2002BecaplerminRP,
  title={Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers},
  author={John M. Embil and Mary K. Nagai},
  journal={Expert Opinion on Biological Therapy},
  year={2002},
  volume={2},
  pages={211 - 218}
}
  • J. Embil, M. Nagai
  • Published 1 February 2002
  • Medicine
  • Expert Opinion on Biological Therapy
Chronic or non-healing lower extremity ulcerations in diabetics are a significant cause of morbidity and mortality, and account for a large proportion of the financial burden related to the care of diabetics. Lower extremity ulcerations develop primarily as a consequence of neuropathy and the goal in addressing any wound is to re-establish tissue integrity as soon as possible. The healing of wounds is a complex procedure involving multiple growth factors, some of which have multiple effects on… 
Becaplermin: A new effective and safe adjuvant topical therapy in patients with chronic neuropathic diabetic foot ulcer
TLDR
To ensure that efficacy and healing of diabetic foot ulcers using becaplermin it is essential to ensure adequate peripheral circulation, sharp debridment, pressure relief and local infection control, and to ensure serious local or systemic unwonted effects.
Evaluation of Recombinant Human Platelet Derived Growth Factor- BB in Healing of Chronic Diabetic Foot Ulcers
TLDR
The incidence of ulcer closure / skin cover at 12 weeks duration in PDGF group was found to be more than in GWC group and this difference was statically significant.
Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers
TLDR
This study did not show any statistically significant improvement in ulcer healing rates after the use of topically applied rhPDGF and was conducted to evaluate its efficacy in the treatment of diabetic foot ulcers.
Heat Shock Protein 90 Versus Conventional Growth Factors in Acute and Diabetic Wound Healing
TLDR
Topical application of eHsp90α accelerated both acute and diabetic wound closure far more effectively than PDGF-BB, which is a common pro-motility factor of all skin cells, and overrides TGFβ inhibition and hyperglycemia.
[Becaplermin gel (Regranex gel)].
  • P. Senet
  • Medicine, Biology
    Annales de dermatologie et de venereologie
  • 2004
Role of Growth Factors in the Treatment of Diabetic Foot Ulceration
TLDR
The subject of this chapter is the role of important growth factors in the treatment of diabetic foot ulceration and the possible promising approaches for foot ulcers management.
A fragment of secreted Hsp90α carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice.
TLDR
It is reported that a 115-aa fragment of secreted Hsp90α (F-5) acts as an unconventional wound healing agent in mice and is potentially more effective and safer agent for healing acute and diabetic wounds.
Becaplermin gel in the treatment of diabetic neuropathic foot ulcers
TLDR
Clearly, further work is needed to clarify whether use of becaplermin is justified in everyday clinical practice, and whether the high cost may be prohibitive for some clinicians, especially in developing countries.
Combination Therapy Accelerates Diabetic Wound Closure
TLDR
Combination AMD3100 and PDGF-BB therapy synergistically improves BM PC mobilization and trafficking, resulting in significantly improved diabetic wound closure and neovascularization.
A fragment of secreted Hsp 90 a carries properties that enable it to accelerate effectively both acute and diabetic wound healing in mice
TLDR
It is reported that a 115-aa fragment of secreted Hsp90a (F-5) acts as an unconventional wound healing agent in mice, and topical application of F-5 peptide promoted acute and diabetic wound closure in mice far more effectively than did PDGF-BB.
...
...

References

SHOWING 1-10 OF 72 REFERENCES
Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy
  • J. Embil, Kimberly M. Papp, C. Lau
  • Medicine
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • 2000
TLDR
Results of this study further confirm the efficacy and safety of becaplermin gel for the treatment of lower extremity diabetic ulcers.
Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model.
TLDR
The results establish that polypeptide growth factors have significant and selective positive influences on healing of full thickness ulcers in the rabbit.
Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
  • E. LeGrand
  • Biology, Medicine
    American journal of surgery
  • 1998
The role of growth factors in the healing of chronic wounds
  • M. Robson
  • Medicine, Biology
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • 1997
TLDR
Only when clinical trials are undertaken in which basic principles related to the biology of wound healing and pharmaceutic considerations are incorporated in the study design will the true potential of various growth factors be appropriately determined.
The role of growth factors in the healing of chronic wounds
TLDR
Only when clinical trials are undertaken in which basic principles related to the biology of wound healing and pharmaceutic considerations are incorporated in the study design will the true potential of various growth factors be appropriately determined.
Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies
TLDR
It is concluded that treatment with becaplermin gel at a dose of 100 μg/g once daily, in conjunction with good ulcer care, is effective and well tolerated in patients with full thickness lower extremity diabetic ulcers.
In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins
Human platelet-derived growth factor (hPDGF) is likely to be important in stimulating tissue repair, based upon its in vivo chemotactic and stimulatory activities for inflammatory cells and
Determination of Endogenous Cytokines in Chronic Wounds
TLDR
Levels of cytokines found in these chronic wounds are much lower than those reported from acute wounds, and may help to explain the differences reported in recent wound healing trials with exogenous cytokines.
...
...